SUBSCRIBE
SUBSCRIBE

GLP-1

Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
Policy
Agreement Reached After Novo Nordisk A/S is Accused of Disguising Salespeople and Dealing Kickbacks
May 1, 2017
 · 
2 min read
Drug Development
Can Psoriatic Arthritis Lift Gilead’s Sinking Ship?
April 20, 2017
 · 
1 min read
Biotech Beach
Nine Blockbuster Drugs To Watch Are Making Their Debut, Aiming At A $16B Prize In 2021
April 11, 2017
 · 
1 min read
Job Trends
A Day In The Life Of A Scientist At AstraZeneca
March 13, 2017
 · 
1 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Tiny Boston Biotech Pieris Nabs $570 Million+ Cancer Deal With French Powerhouse Servier
January 5, 2017
 · 
2 min read
Genetown
After Rough 2016, Markets To Open For Emerging Biotech
December 14, 2016
 · 
1 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Pharm Country
Why Investors Should Buy (and Avoid) Merck & Co.
November 11, 2016
 · 
2 min read
Biotech Bay
Celgene Pitted Against Gilead, Biogen In Crohn’s Drug Battle
October 19, 2016
 · 
1 min read
BioMidwest
ImageQuantify.com Announces New IQbot For Quantitative Image Analysis Of Eotaxin
September 22, 2016
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
Gilead Terminates Phase II/III Study of Ulcerative Colitis Drug
September 21, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
August 29, 2025
 · 
10 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
August 26, 2025
 · 
11 min read
Press Releases
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
August 20, 2025
 · 
7 min read
Press Releases
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
August 19, 2025
 · 
15 min read
Press Releases
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
August 18, 2025
 · 
3 min read
Press Releases
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 18, 2025
 · 
7 min read
Press Releases
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
August 18, 2025
 · 
3 min read
Press Releases
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 14, 2025
 · 
11 min read
Press Releases
Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management
August 14, 2025
 · 
6 min read
Press Releases
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
August 13, 2025
 · 
8 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
August 7, 2025
 · 
10 min read
Press Releases
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
August 6, 2025
 · 
3 min read
Press Releases
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
August 6, 2025
 · 
8 min read
Press Releases
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 6, 2025
 · 
12 min read
Press Releases
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
August 6, 2025
 · 
5 min read
Press Releases
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
August 5, 2025
 · 
9 min read
Press Releases
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
August 5, 2025
 · 
8 min read
Press Releases
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
August 5, 2025
 · 
5 min read
Press Releases
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
July 30, 2025
 · 
7 min read
Press Releases
Hohenstein Medical Earns GLP Certification for Medical Device Testing
July 30, 2025
 · 
3 min read
Load More